Central Nervous System Drugs
Learning Objectives
By the end of this page you should be able to:
- Classify the major CNS drug groups (sedative-hypnotics, anticonvulsants, antidepressants, antipsychotics, opioids) by their primary site and mechanism of action.
- Explain how benzodiazepines potentiate GABA-A receptors and why this differs mechanistically from barbiturates.
- Describe how SSRIs increase synaptic serotonin and link this mechanism to their delayed clinical onset.
- Compare typical and atypical antipsychotics in terms of dopamine receptor blockade and side-effect profile.
- Identify the opioid receptor subtypes and predict the clinical and toxic effects of opioid agonism.
- Recognize the serious safety signals associated with each drug class (respiratory depression, withdrawal seizures, extrapyramidal symptoms, serotonin syndrome).
Quick Answer
CNS drugs act on the brain and spinal cord to either dampen (sedatives, anticonvulsants, opioids) or modulate (antidepressants, antipsychotics) neural signaling. Most work by changing neurotransmitter availability or receptor activity — benzodiazepines boost inhibitory GABA transmission, SSRIs raise synaptic serotonin, antipsychotics block dopamine D2 receptors, and opioids activate mu receptors to block pain signals while also suppressing the brainstem's respiratory drive. They matter clinically because they treat some of the most common conditions in medicine (anxiety, epilepsy, depression, psychosis, pain) but also carry the highest risk of dependence, withdrawal, and fatal overdose among all drug classes, which is why understanding their mechanisms is central to safe prescribing.
Classification of CNS Drugs
CNS drugs are grouped by the clinical problem they treat, but the more useful exam framework is to know what neurotransmitter system each class touches — that single fact predicts most of the mechanism, side effects, and drug interactions you'll be tested on.
Sedative-Hypnotics
These drugs reduce neural excitability, mainly through the inhibitory neurotransmitter GABA.
Definition. Sedative-hypnotics depress CNS activity to produce calming (sedation) or sleep-inducing (hypnotic) effects.
Explanation — how they work. GABA-A receptors are chloride channels. When GABA binds, chloride flows into the neuron, hyperpolarizing it and making it harder to fire. Benzodiazepines (diazepam, lorazepam, alprazolam) bind a separate site on the GABA-A receptor and increase the frequency of channel opening — but only in the presence of GABA, which is why they have a ceiling effect and are relatively safe in overdose. Barbiturates (phenobarbital) bind a different site and increase the duration the channel stays open, and at high doses can open the channel even without GABA — this is why barbiturate overdose causes fatal respiratory depression far more easily than benzodiazepine overdose. Z-drugs (zolpidem, zaleplon) are chemically unrelated to benzodiazepines but act at the same site, with more selectivity for the alpha-1 GABA-A subunit responsible for sedation rather than anxiolysis.
Example. A patient with acute panic attack is given IV lorazepam; within minutes, chloride influx increases, neuronal firing slows, and the patient's anxiety and tachycardia settle.
Real-world example. Diazepam is first-line for alcohol withdrawal precisely because alcohol also potentiates GABA-A receptors — the benzodiazepine substitutes for alcohol's effect and is then tapered slowly to prevent withdrawal seizures.
Why it matters. Benzodiazepines are among the most prescribed psychiatric drugs worldwide, but tolerance and physical dependence develop within weeks, and abrupt discontinuation can cause life-threatening withdrawal seizures — never stop them abruptly after prolonged use.
Common misunderstanding. Students often assume benzodiazepines and barbiturates work "the same way because both boost GABA." The board-relevant distinction is frequency vs. duration of channel opening, and this single difference explains why flumazenil (a benzodiazepine antagonist) does not reliably reverse barbiturate overdose.
Anticonvulsants
Definition. Anticonvulsants (antiepileptics) raise the seizure threshold by stabilizing hyperexcitable neurons.
Explanation. Three mechanisms dominate the exam: (1) blocking voltage-gated sodium channels in their inactive state to prevent rapid repetitive firing (phenytoin, carbamazepine, lamotrigine); (2) enhancing GABAergic inhibition (valproate, benzodiazepines, phenobarbital); (3) blocking T-type calcium channels in thalamic neurons, which is specific to absence seizures (ethosuximide, valproate). Valproate is unusual because it does all three, which is part of why it is broad-spectrum.
Example. A patient with absence seizures is treated with ethosuximide, which blocks the thalamic T-type Ca2+ channels driving the 3 Hz spike-wave discharges seen on EEG.
Real-world example. Carbamazepine is used for both generalized tonic-clonic seizures and trigeminal neuralgia because sodium channel blockade also dampens the ectopic firing in irritated nerve fibers.
Why it matters. Choosing the wrong anticonvulsant can worsen seizures — ethosuximide and valproate work for absence seizures, but sodium-channel blockers like carbamazepine can actually aggravate absence seizures.
Common misunderstanding. Students assume "anticonvulsant" is one homogeneous mechanism. In reality the drug must match the seizure type, and mismatching mechanism to seizure type is a classic wrong-answer trap in exams.
Antidepressants
Definition. Antidepressants correct monoamine (serotonin, norepinephrine, dopamine) signaling deficits implicated in mood disorders.
Explanation. SSRIs (fluoxetine, sertraline, escitalopram) block the serotonin transporter (SERT) on the presynaptic neuron, preventing serotonin reuptake so it accumulates in the synaptic cleft and keeps stimulating postsynaptic receptors. SNRIs (venlafaxine, duloxetine) block both SERT and the norepinephrine transporter. TCAs (amitriptyline) do the same but also block histamine, muscarinic, and alpha-1 receptors, which explains their heavier side-effect burden. MAOIs block the enzyme that degrades monoamines, requiring dietary tyramine restriction to avoid hypertensive crisis. Clinically, reuptake blockade happens within hours, but mood improvement takes 2–4 weeks — the lag is attributed to slower downstream changes such as receptor downregulation and increased neuroplasticity (e.g., BDNF signaling), not the reuptake block itself.
Example. A patient started on sertraline is warned that anxiety may transiently worsen in the first week (due to initial serotonin receptor overstimulation) before improving by week 3–4.
Real-world example. Combining an SSRI with an MAOI (or starting one too soon after stopping the other) can cause serotonin syndrome — hyperthermia, clonus, agitation — which is why a washout period is mandatory when switching classes.
Why it matters. SSRIs are first-line for depression and most anxiety disorders because of their comparatively favorable side-effect and safety profile in overdose compared to TCAs, which are cardiotoxic (QT prolongation) in overdose.
Common misunderstanding. A common mistake is expecting SSRIs to work immediately like a sedative. Because they act through downstream neuroplastic changes rather than an instant chloride shift, clinical benefit is delayed — patients should be counseled not to stop the drug early for "not working."
Antipsychotics
Definition. Antipsychotics reduce positive symptoms of psychosis (hallucinations, delusions) primarily by blocking dopamine D2 receptors in the mesolimbic pathway.
Explanation. Typical (first-generation) antipsychotics like haloperidol block D2 receptors broadly across all four dopamine pathways, so while they control the mesolimbic pathway that drives psychosis, they also block the nigrostriatal pathway, causing extrapyramidal symptoms (parkinsonism, akathisia, tardive dyskinesia) and the tuberoinfundibular pathway, causing hyperprolactinemia. Atypical (second-generation) antipsychotics like risperidone and olanzapine also block 5-HT2A serotonin receptors, which paradoxically restores some dopamine release in the nigrostriatal pathway — this is why atypicals cause fewer motor side effects but more metabolic side effects (weight gain, dyslipidemia, diabetes).
Example. A patient with acute schizophrenia exacerbation given haloperidol develops acute dystonia (sustained muscle contraction) within days — treated with an anticholinergic like benztropine, which restores the dopamine-acetylcholine balance in the striatum.
Real-world example. Clozapine, an atypical antipsychotic, is reserved for treatment-resistant schizophrenia because of its risk of agranulocytosis, requiring mandatory regular blood count monitoring.
Why it matters. Choosing typical vs. atypical is a real prescribing decision balancing motor side effects against metabolic risk, and it comes up constantly in exam vignettes asking you to identify a drug from its side-effect pattern.
Common misunderstanding. Students often think atypicals have "no side effects" because they cause fewer EPS. In fact, the metabolic syndrome risk from atypicals can be more dangerous long-term than the motor effects of typicals.
Opioid Analgesics
Definition. Opioids relieve pain by activating opioid receptors that are normally engaged by the body's own endorphins and enkephalins.
Explanation. There are three main receptor subtypes — mu, kappa, and delta — all G-protein coupled and inhibitory. Mu receptor activation (by morphine, fentanyl, oxycodone) is responsible for the analgesia, euphoria, and — critically — the respiratory depression that makes opioid overdose fatal, because mu receptors in the brainstem's respiratory centers reduce the response to rising CO2. Mu activation also slows GI motility (constipation, the one side effect that never develops tolerance) and causes miosis (pinpoint pupils), a classic bedside sign of opioid toxicity. Buprenorphine is a partial mu agonist — it activates the receptor weakly, giving a ceiling effect on respiratory depression, which is why it's used in opioid use disorder treatment. Naloxone is a competitive mu antagonist with higher receptor affinity, used to rapidly reverse overdose.
Example. A patient overdosing on heroin presents with the toxic triad — pinpoint pupils, respiratory depression, and decreased consciousness — reversed within minutes by IV naloxone.
Real-world example. Postoperative pain protocols increasingly favor multimodal analgesia (NSAIDs plus limited opioids) specifically to reduce mu receptor exposure and the risk of dependence.
Why it matters. Opioids are the single largest cause of preventable drug-related deaths worldwide because the same receptor that controls pain also controls the drive to breathe — this dual action is the central safety concept of the entire drug class.
Common misunderstanding. Students sometimes think tolerance develops equally to all opioid effects. Tolerance to analgesia and euphoria develops quickly, but tolerance to constipation and miosis develops slowly or not at all — which is why long-term opioid patients almost always need a bowel regimen.
Key Terms
| Term | Definition |
|---|---|
| GABA-A receptor | A ligand-gated chloride channel; the main inhibitory receptor in the CNS and the target of benzodiazepines, barbiturates, and alcohol |
| Serotonin transporter (SERT) | The presynaptic protein that recycles serotonin from the synapse; blocked by SSRIs and SNRIs |
| Extrapyramidal symptoms (EPS) | Movement disorders (dystonia, parkinsonism, akathisia, tardive dyskinesia) caused by dopamine D2 blockade in the nigrostriatal pathway |
| Serotonin syndrome | A toxic state of excess serotonergic activity — hyperthermia, clonus, agitation — from combining serotonergic drugs (e.g., SSRI + MAOI) |
| Mu receptor | The primary opioid receptor subtype responsible for analgesia, euphoria, and respiratory depression |
| Ceiling effect | A pharmacologic property where increasing the dose beyond a point produces no additional effect (seen with benzodiazepine respiratory depression and buprenorphine) |
| Tolerance | A reduced drug response after repeated exposure, requiring higher doses for the same effect |
| Withdrawal | A rebound physiological state that occurs when a chronically used CNS depressant is stopped abruptly |
Common Mistakes
Misconception 1: "Benzodiazepines and barbiturates are basically interchangeable since both act on GABA-A receptors." Why it's wrong: They bind different sites and change different channel properties (frequency vs. duration of opening). Correct explanation: Barbiturates can open the chloride channel independent of GABA at high doses, causing a much narrower margin of safety and greater overdose lethality than benzodiazepines, which require GABA to be present.
Misconception 2: "SSRIs should relieve depression within a day or two, like a sedative relieves anxiety." Why it's wrong: This confuses the pharmacokinetic action (reuptake blockade, which is immediate) with the pharmacodynamic clinical effect (mood improvement, which depends on slower neuroadaptive changes). Correct explanation: Clinical improvement typically takes 2–4 weeks because it depends on downstream receptor and neuroplastic changes, not the initial reuptake blockade — patients need counseling to continue the medication despite a lack of immediate effect.
Misconception 3: "Atypical antipsychotics are safer than typical antipsychotics overall." Why it's wrong: "Safer" depends on which side effects you're weighing — atypicals trade motor side effects for metabolic ones. Correct explanation: Atypicals cause fewer extrapyramidal symptoms because of added 5-HT2A blockade, but they carry a significantly higher risk of weight gain, dyslipidemia, and diabetes, which must be monitored just as seriously.
Comparison and Connections
| Drug class | Primary target | Onset of therapeutic effect | Overdose risk | Classic side effect |
|---|---|---|---|---|
| Benzodiazepines | GABA-A (frequency) | Minutes | Low (ceiling effect) unless combined with other depressants | Sedation, dependence |
| Barbiturates | GABA-A (duration) | Minutes | High (no ceiling) | Fatal respiratory depression |
| SSRIs | Serotonin transporter | 2–4 weeks | Low | Sexual dysfunction, GI upset |
| Typical antipsychotics | D2 (all pathways) | Days to weeks | Moderate | Extrapyramidal symptoms |
| Atypical antipsychotics | D2 + 5-HT2A | Days to weeks | Moderate | Weight gain, metabolic syndrome |
| Opioids (mu agonists) | Mu receptor | Minutes | High | Respiratory depression, constipation |
Practice Questions
Recall 1. Which receptor do benzodiazepines act on, and what ion does it conduct? Answer guidance: GABA-A receptor; conducts chloride ions.
Recall 2. Name the three opioid receptor subtypes. Answer guidance: Mu, kappa, and delta.
Understanding 1. Explain why barbiturate overdose is more dangerous than benzodiazepine overdose despite both acting on the same receptor family. Answer guidance: Benzodiazepines only increase the frequency of GABA-A channel opening and need GABA present (ceiling effect), while barbiturates increase channel open duration and can activate the channel without GABA at high doses, removing the safety ceiling and allowing profound respiratory depression.
Understanding 2. Why does clinical improvement with SSRIs lag behind the immediate biochemical blockade of serotonin reuptake? Answer guidance: The mood benefit depends on slower downstream adaptations — receptor sensitivity changes and increased neuroplasticity/BDNF signaling — not the reuptake block itself, which explains the 2–4 week delay.
Application 1. A patient on haloperidol develops rigidity, tremor, and a shuffling gait after several weeks. Which pathway is responsible, and what class of drug could help? Answer guidance: The nigrostriatal dopamine pathway is being blocked, causing drug-induced parkinsonism; an anticholinergic (e.g., benztropine) restores the dopamine-acetylcholine balance and reduces symptoms.
Application 2. A patient found unconscious with pinpoint pupils and a respiratory rate of 4/min is given naloxone. Explain the pharmacological basis for why this reverses the overdose. Answer guidance: Naloxone is a competitive mu-receptor antagonist with higher affinity than the opioid; it displaces the opioid from mu receptors in the brainstem respiratory centers, restoring normal respiratory drive.
Analysis 1. Compare why ethosuximide is effective for absence seizures but carbamazepine is not, even though both are anticonvulsants. Answer guidance: Absence seizures arise from abnormal T-type calcium channel–driven thalamocortical oscillations; ethosuximide blocks these channels directly. Carbamazepine works via sodium channel blockade, which does not address the calcium-channel mechanism and can even worsen absence seizures.
Analysis 2. A patient switched from an MAOI to an SSRI without an adequate washout period develops fever, muscle rigidity, and agitation. Analyze what happened and why the washout period matters. Answer guidance: This is serotonin syndrome caused by additive serotonergic activity — the MAOI prevents monoamine breakdown while the SSRI blocks reuptake, so serotonin accumulates excessively. A washout period allows the irreversibly inhibited MAO enzyme to regenerate before adding a second serotonergic mechanism.
FAQ
Q1: Why do benzodiazepines cause dependence but are still widely prescribed? They are extremely effective for acute anxiety, seizures, and alcohol withdrawal, and short-term use carries low dependence risk. The problem arises with prolonged, continuous use, so guidelines recommend the lowest effective dose for the shortest duration.
Q2: Why don't opioids and benzodiazepines mix well? Both depress the CNS through different mechanisms, but combined they produce additive respiratory depression — this drug combination is a leading cause of overdose deaths.
Q3: Why do some anticonvulsants also treat mood disorders or nerve pain? Drugs like valproate (mood stabilization) and carbamazepine (trigeminal neuralgia, neuropathic pain) work by stabilizing neuronal excitability generally, which is useful anywhere neurons are firing abnormally, not just in seizures.
Q4: Is it true that all antidepressants risk suicidal ideation? There is a labeled warning for increased suicidal thinking in children, adolescents, and young adults, particularly in the first weeks of treatment, which is why close monitoring is recommended at treatment initiation, not a reason to avoid treatment altogether.
Q5: Why is naloxone safe to give even if the diagnosis of opioid overdose is uncertain? Naloxone has no significant effect on someone without opioids in their system, so it is given empirically in any suspected overdose without waiting for confirmation.
Quick Revision
- GABA-A receptor = inhibitory chloride channel; target of benzodiazepines (frequency of opening) and barbiturates (duration of opening).
- Barbiturates have no ceiling effect and are more lethal in overdose than benzodiazepines.
- Z-drugs (zolpidem) act at the same GABA-A site but selectively on the alpha-1 subunit — sedation with less anxiolysis.
- Anticonvulsant mechanisms: Na+ channel block (phenytoin, carbamazepine), GABA enhancement (valproate), T-type Ca2+ block (ethosuximide — absence seizures only).
- SSRIs block serotonin reuptake (SERT); clinical benefit is delayed 2–4 weeks due to downstream neuroadaptation.
- SSRI + MAOI (without washout) = risk of serotonin syndrome (fever, clonus, agitation).
- Typical antipsychotics block D2 broadly → more extrapyramidal symptoms; atypicals add 5-HT2A blockade → fewer EPS but more metabolic side effects.
- Opioid mu receptor activation causes analgesia, euphoria, respiratory depression, constipation (no tolerance), and miosis.
- Naloxone: competitive mu antagonist, reverses opioid overdose; buprenorphine: partial mu agonist with a ceiling effect, used in opioid use disorder.
- Constipation and miosis are the opioid effects that tolerance rarely develops to — analgesia and euphoria tolerance develop fast.
- Never abruptly stop benzodiazepines, barbiturates, or opioids after prolonged use — all carry withdrawal risk, and benzodiazepine/barbiturate withdrawal can be seizure-inducing and fatal.
Related Topics
Prerequisites: Basic neurotransmitter physiology (GABA, dopamine, serotonin, norepinephrine), synaptic transmission, receptor pharmacology (agonist vs. antagonist vs. partial agonist).
Related Topics: Autonomic nervous system pharmacology, general and local anesthetics, drugs used in Parkinson's disease (dopamine pathway comparison), pain management and analgesic ladder.
Next Topics: Anesthetic agents and neuromuscular blockers, substance use disorder pharmacology, drug interactions and toxicology (overdose management).